2. Academic Validation
  3. Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation

Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation

  • Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):381-6. doi: 10.1073/pnas.0809057106.
Peter J Crouch 1,  Lin Wai Hung,  Paul A Adlard,  Mikhalina Cortes,  Varsha Lal,  Gulay Filiz,  Keyla A Perez,  Milawaty Nurjono,  Aphrodite Caragounis,  Tai Du,  Katrina Laughton,  Irene Volitakis,  Ashley I Bush,  Qiao-Xin Li,  Colin L Masters,  Roberto Cappai,  Robert A Cherny,  Paul S Donnelly,  Anthony R White,  Kevin J Barnham
Affiliations

Affiliation

  • 1 Department of Pathology, Centre for Neuroscience, School of Chemistry, and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victorial, 3010, Australia.
PMID: 19122148 DOI: 10.1073/pnas.0809057106
Abstract

Cognitive decline in Alzheimer's disease (AD) involves pathological accumulation of synaptotoxic amyloid-beta (Abeta) oligomers and hyperphosphorylated tau. Because recent evidence indicates that glycogen synthase kinase 3beta (GSK3beta) activity regulates these neurotoxic pathways, we developed an AD therapeutic strategy to target GSK3beta. The strategy involves the use of copper-bis(thiosemicarbazonoto) complexes to increase intracellular copper bioavailability and inhibit GSK3beta through activation of an Akt signaling pathway. Our lead compound Cu(II)(gtsm) significantly inhibited GSK3beta in the brains of APP/PS1 transgenic AD model mice. Cu(II)(gtsm) also decreased the abundance of Abeta trimers and phosphorylated tau, and restored performance of AD mice in the Y-maze test to levels expected for cognitively normal Animals. Improvement in the Y-maze correlated directly with decreased Abeta trimer levels. This study demonstrates that increasing intracellular copper bioavailability can restore cognitive function by inhibiting the accumulation of neurotoxic Abeta trimers and phosphorylated tau.

Figures
Products